Abstract:Background: Allergic drug reaction or drug allergy is an immunologically mediated drug hypersensitivity reaction (DHR). G-protein coupled receptors (GPCRs) are common drug targets and communicate extracellular signals that initiate cellular responses. Recent evidence shows that GPCR MRGPRX2 is of major importance in IgE-independent pseudo-allergic DHRs based on the suspected interactions between many FDA-approved peptidergic compounds and MRGPRX2. Objective: Our aim was to uncover novel MRGPRX2-selective and -potent agonists as drug candidates responsible for clinical features of pseudo-allergic DHRs. Methods: We conducted a primary high-throughput screening (HTS), coupled with mutagenesis targeting the MRGPRX2 N62S mutation, on a panel of 3,456 library compounds. We discovered pharmacologically active hit compounds as agonists of the MRGPRX2 protein according to high degrees of potency evaluated by the calcium response and validated by the degranulation assay. Using the molecular tool Forge, we also characterized the structure-activity relationship shared by identified hit compounds. Results: The alternative allele of single nucleotide polymorphism rs10833049 (N62S) in MRGPRX2 demonstrated loss-of-function property in response to substance P and antineoplastic agent daunorubicin hydrochloride. We applied a unique assay system targeting the N62S mutation to the HTS and identified 84 MRGPRX2-selective active hit compounds representing diverse classes according to primary drug indications. The top five highly represented groups included fluoroquinolone and non-fluoroquinolone antibiotics; antidepressive/antipsychotic; antihistaminic and antineoplastic agents. We classified hit compounds into 14 clusters representing a variety of chemical and drug classes beyond those reported, such as opioids, neuromuscular blocking agents, and fluoroquinolones. We further demonstrated MRGPRX2-dependent degranulation in the human mast cell line LAD2 cells induced by three novel agonists representing the non-fluoroquinolone antibiotics (bacitracin A), anti-allergic agents (brompheniramine maleate) and tyrosine-kinase inhibitors (imatinib mesylate). Conclusion: Our findings could facilitate the development of interventions for personalized prevention and treatment of DHRs, as well as future pharmacogenetic investigations of MRGPRX2 in relevant disease cohorts.

Screening herbal and natural product libraries to aid discovery of novel allosteric modulators of human P2X7

P2X7 receptors exhibit at least three modes of allosteric antagonism

Druggable negative allosteric site of P2X3 receptors

Discover Natural Compounds As Potential Phosphodiesterase-4B Inhibitors Via Computational Approaches

Identification of Novel P2X7R Antagonists by Using Structure‐based Virtual Screening and Cell‐based Assays

Development of an Allostery Responsive Chromatographic Method for Screening Potential Allosteric Modulator of Beta2-adrenoceptor from a Natural Product-Derived DNA-Encoded Chemical Library

P2X 7 receptors exhibit at least three modes of allosteric antagonism

Biological screening of a unique drug library targeting MRGPRX2

The rational search for PDE10A inhibitors from Sophora flavescens roots using pharmacophore‑ and docking‑based virtual screening.

Discovery of Novel Antagonists on Β2-Adrenoceptor from Natural Products Using a Label-Free Cell Phenotypic Assay.

Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Structural insights into the orthosteric inhibition of P2X receptors by non-ATP-analog antagonists

Structure-based Discovery of Selective Positive Allosteric Modulators of Antagonists for the M2 Muscarinic Acetylcholine Receptor.

Abstract P2154: A Novel Allosteric Modulator of the Β 1 AR Identified by DNA-encoded Small Molecule Library Screening Demonstrates Unique Pharmacology and Function

Exploring P2X receptor activity: A journey from cellular impact to electrophysiological profiling

Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists

Screening and toxicity evaluation of natural compounds as adenosine 2a and 2b receptor ligands: insights from molecular docking, dynamics, and ADMET analysis

The Rational Search for PDE10A Inhibitors from Sophoraï¿½flavescens Roots Using Pharmacophore‑ and Docking‑based Virtual Screening

Identification of Novel Antagonists Targeting Cannabinoid Receptor 2 Using a Multi-Step Virtual Screening Strategy

Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay

Docking-Based Virtual Screening of Potential Human P2y12 Receptor Antagonists